NervGen Pharma Corp. (NGEN)

NervGen Pharma Statistics

Total Valuation

NervGen Pharma has a market cap or net worth of $302.68 million. The enterprise value is $291.85 million.

Market Cap	302.68M
Enterprise Value	291.85M

Important Dates

The next estimated earnings date is Friday, May 22, 2026.

Earnings Date	May 22, 2026
Ex-Dividend Date	n/a

Share Statistics

NervGen Pharma has 80.93 million shares outstanding. The number of shares has increased by 7.44% in one year.

Current Share Class	80.93M
Shares Outstanding	80.93M
Shares Change (YoY)	+7.44%
Shares Change (QoQ)	+0.47%
Owned by Insiders (%)	2.50%
Owned by Institutions (%)	4.13%
Float	68.91M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	n/a
Forward PS	n/a
PB Ratio	120.30
P/TBV Ratio	137.63
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Enterprise Valuation

EV / Earnings	n/a
EV / Sales	n/a
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	n/a

Financial Position

The company has a current ratio of 1.16, with a Debt / Equity ratio of 0.00.

Current Ratio	1.16
Quick Ratio	1.12
Debt / Equity	0.00
Debt / EBITDA	n/a
Debt / FCF	n/a
Interest Coverage	n/a

Financial Efficiency

Return on equity (ROE) is -1,457.57% and return on invested capital (ROIC) is -508.29%.

Return on Equity (ROE)	-1,457.57%
Return on Assets (ROA)	-73.42%
Return on Invested Capital (ROIC)	-508.29%
Return on Capital Employed (ROCE)	-721.31%
Weighted Average Cost of Capital (WACC)	9.08%
Revenue Per Employee	n/a
Profits Per Employee	n/a
Employee Count	n/a
Asset Turnover	n/a
Inventory Turnover	n/a

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +47.24% in the last 52 weeks. The beta is 0.88, so NervGen Pharma's price volatility has been lower than the market average.

Beta (5Y)	0.88
52-Week Price Change	+47.24%
50-Day Moving Average	3.95
200-Day Moving Average	3.59
Relative Strength Index (RSI)	44.48
Average Volume (20 Days)	169,699

Short Selling Information

The latest short interest is 1.27 million, so 1.58% of the outstanding shares have been sold short.

Short Interest	1.27M
Short Previous Month	1.43M
Short % of Shares Out	1.58%
Short % of Float	1.85%
Short Ratio (days to cover)	6.23

Income Statement

Revenue	n/a
Gross Profit	n/a
Operating Income	-18.29M
Pretax Income	-32.18M
Net Income	-32.18M
EBITDA	-18.25M
EBIT	-18.29M
Earnings Per Share (EPS)	-$0.44

Balance Sheet

The company has $16.10 million in cash and $6,104 in debt, with a net cash position of $16.09 million or $0.20 per share.

Cash & Cash Equivalents	16.10M
Total Debt	6,104
Net Cash	16.09M
Net Cash Per Share	$0.20
Equity (Book Value)	2.54M
Book Value Per Share	0.03
Working Capital	2.24M

Cash Flow

Operating Cash Flow	-14.22M
Capital Expenditures	n/a
Depreciation & Amortization	40,691
Net Borrowing	-73,605
Free Cash Flow	-14.22M
FCF Per Share	-$0.18

Margins

Gross Margin	n/a
Operating Margin	n/a
Pretax Margin	n/a
Profit Margin	n/a
EBITDA Margin	n/a
EBIT Margin	n/a
FCF Margin	n/a

Dividends & Yields

NervGen Pharma does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-7.44%
Shareholder Yield	-7.44%
Earnings Yield	-10.45%
FCF Yield	-4.62%

Analyst Forecast

The average price target for NervGen Pharma is $18.00, which is 381.28% higher than the current price. The consensus rating is "Strong Buy".

Price Target	$18.00
Price Target Difference	381.28%
Analyst Consensus	Strong Buy
Analyst Count	1
Revenue Growth Forecast (5Y)	n/a
EPS Growth Forecast (5Y)	n/a

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Altman Z-Score	n/a
Piotroski F-Score	2